MHRA approved the UK's first GLP-1 weight-loss tablet
The MHRA licensed oral semaglutide, branded Wegovy, for weight management on 11 June. It is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition. Treatment starts at the lowest strength and steps up at intervals of at least a month. The tablet must be swallowed whole on an empty stomach with a sip of water after fasting for at least eight hours. The MHRA said patients already on the weekly injection privately can move straight across to the highest tablet strength.
What this actually means
The headline is that you no longer need a needle. The detail is that you do need an empty stomach and an eight-hour fast, every single day, which is a real constraint the coverage tends to skip.
Two things worth being clear on. First, the eligibility criteria are the same BMI thresholds as the injection, so a tablet does not widen who qualifies. Second, it is not available on the NHS, only privately, so the barrier for most people has moved from needle to cost.
It is also not the same as Rybelsus, which is an older semaglutide tablet licensed only for type 2 diabetes. Same drug, different strengths, different licence. That confusion is going to be everywhere.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.